54665-92-8 Usage
Uses
Used in Medicinal Chemistry:
4,7-Dichloro-2-phenyl-quinazoline is utilized as a key intermediate in the synthesis of various pharmaceuticals for its unique structural and functional attributes. Its presence in drug molecules can modulate their pharmacological properties, such as potency, selectivity, and bioavailability.
Used in Drug Development:
In the pharmaceutical industry, 4,7-Dichloro-2-phenyl-quinazoline serves as a building block for the creation of novel therapeutic agents. Its chemical versatility allows for the design of drugs targeting a wide range of diseases, including cancer, inflammatory disorders, and infectious diseases.
Used in Chemical Research:
4,7-Dichloro-2-phenyl-quinazoline is employed as a research tool in chemical laboratories to study the structure-activity relationships of quinazoline-based compounds. It aids in understanding the molecular mechanisms of action and optimizing the drug candidates for clinical applications.
Used in Biochemical Studies:
4,7-Dichloro-2-phenyl-quinazoline is also used in biochemical research to probe the interactions between quinazoline-based drugs and their biological targets, such as enzymes, receptors, or other macromolecules. This helps in elucidating the molecular basis of drug action and resistance, thereby facilitating the development of more effective therapeutic strategies.
Check Digit Verification of cas no
The CAS Registry Mumber 54665-92-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,4,6,6 and 5 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 54665-92:
(7*5)+(6*4)+(5*6)+(4*6)+(3*5)+(2*9)+(1*2)=148
148 % 10 = 8
So 54665-92-8 is a valid CAS Registry Number.
InChI:InChI=1S/C14H8Cl2N2/c15-10-6-7-11-12(8-10)17-14(18-13(11)16)9-4-2-1-3-5-9/h1-8H
54665-92-8Relevant academic research and scientific papers
Design, Synthesis, and Pharmacological Characterization of N-(4-(2 (6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)yl)ethyl)phenyl)quinazolin-4-amine Derivatives: Novel Inhibitors Reversing P-Glycoprotein-Mediated Multidrug Resistance
Qiu, Qianqian,Liu, Baomin,Cui, Jian,Li, Zheng,Deng, Xin,Qiang, Hao,Li, Jieming,Liao, Chen,Zhang, Bo,Shi, Wei,Pan, Miaobo,Huang, Wenlong,Qian, Hai
, p. 3289 - 3302 (2017/05/05)
P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) is a principal obstacle for successful cancer chemotherapy. A novel P-gp inhibitor with a quinazoline scaffold, 12k, was considered to be the most promising for in-depth study. 12k possessed high potency (EC50 = 57.9 ± 3.5 nM), low cytotoxicity, and long duration of activity in reversing doxorubicin (DOX) resistance in K562/A02 cells. 12k also boosted the potency of other MDR-related cytotoxic agents with different structures, increased accumulation of DOX, blocked P-gp-mediated Rh123 efflux, and suppressed P-gp ATPase activity in K562/A02 MDR cells. However, 12k did not have any effects on CYP3A4 activity or P-gp expression. In particular, 12k had a good half-life and oral bioavailability and displayed no influence on DOX metabolism to obviate the side effects closely related to increased plasma concentrations of cytotoxic agents in vivo.
6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS
-
Page/Page column 419-420, (2008/06/13)
Compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein XI, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
